Organic Process Research & Development 2003, 7, 407−411
Highly Efficient Asymmetric Hydrogenation of 2-Methylenesuccinamic Acid
Using a Rh-DuPHOS Catalyst
Christopher J. Cobley,* Ian C. Lennon, C e´ line Praquin, and Antonio Zanotti-Gerosa
Dowpharma, Chirotech Technology Ltd., A Subsidiary of The Dow Chemical Company, Cambridge Science Park,
Unit 321, Milton Road, Cambridge CB4 0WG, U.K.
Robert B. Appell, Christian T. Goralski, and Angela C. Sutterer
Dowpharma, The Dow Chemical Company, 1710 Building, Midland, Michigan 48674, U.S.A.
Abstract:
Scheme 1. Synthesis of (R) or (S)-methylsuccinamic acid
via asymmetric hydrogenation
An extremely efficient route to highly enantiomerically enriched
2
-methylsuccinamic acid via asymmetric hydrogenation has
been developed. By using [(S,S)-Et-DuPHOS Rh COD]BF as
4
the precatalyst under a set of broadly optimised process
parameters, (R)-2-methylsuccinamic acid was obtained in 96%
ee at a substrate-to-catalyst ratio (S/C) of 100000 (average
-
1
turnover frequency ∼13000 h ). The exclusion of chloride-
containing contaminants in the substrate was found to be crucial
in obtaining exceptionally low catalyst loadings. This material
could be upgraded with a single-crystal digestion to yield (R)-
genation catalyst for the preparation of 2 together with initial
investigations into process optimisation.
Results and Discussion
2
-methylsuccinamic acid in >99.5% ee containing less than 1
The hydrogenation substrate, 2-methylenesuccinamic acid
ppm rhodium.
(2), was obtained by treatment of itaconic anhydride with
aqueous ammonium hydroxide followed by neutralization
of excess base with dilute hydrochloric acid (Scheme 1).5
Analysis of the substrate thus obtained indicated a retention
of chloride of approximately 1 wt %. Replacement of
hydrochloric acid by sulfuric acid produced a chloride-free
product. As will be described below, the presence or absence
of this chloride-containing impurity was found to have a
dramatic effect on the overall reaction rates obtainable.
Having chosen a set of standard conditions that we have
found to be routinely applicable for early-stage catalyst
Introduction
Both enantiomers of 2-methylsuccinamic acid (2) are
important chiral building blocks for the synthesis of numer-
ous biologically active compounds.1 A synthetic approach
to enantiomerically enriched 2 via asymmetric hydrogenation
of 2-methylenesuccinamic acid (Scheme 1) has potentially
the combined advantages of high selectivity, high efficiency,
and the availability of both enantiomers by using opposite
enantiomers of the chosen catalyst. Such an approach has
been previously reported, albeit with moderate enantiose-
lectivities, high catalyst loadings, and long reaction times
,2
2
screening (18 h at 60 psi H , 0.2 M solution of substrate in
MeOH, room temperature, and S/C of 100), the hydrogena-
tion study commenced with an initial screen of several
3
,4
[
(diphosphine)Rh(COD)]BF
4
precatalysts containing the
(75-77% ee with a molar substrate-to-catalyst ratio (S/C)
6
-8
diphosphines shown in Figure 1.
All reactions gave
5
of 100 to 1000 over 20 h). Herein we report a study
performed to identify a more efficient asymmetric hydro-
complete conversion, and the resulting enantioselectivities
are represented in Figure 2. Interestingly, under these
conditions, the presence of the chloride-containing impurity
had no overall effect on the general trend observed for
enantioselectivity.
*
Author for correspondence. E-mail: ccobley@dow.com.
(1) For an example of the use of (R)-2-methylsuccinamic acid, see: (a) Ikeura,
Y.; Doi, T.; Fujishima, A.; Natsugari, H. Chem. Commun. 1998, 2141-
2
142. (b) Natsugari, H.; Ikeura, Y.; Kamo, I.; Ishimaru, T.; Ishichi, Y.;
With these initial results in hand, four precatalysts were
identified as candidates worthy of further examination,
Fujishima, A.; Tanaka, T.; Kasahara, F.; Kawada, M.; Natsugari, H. J. Med.
Chem. 1999, 42, 3982-3993.
2) For an example of the use of (S)-2-methylsuccinamic acid, see: Fuji, T.;
Ogawa, N. Tetrahedron Lett. 1972, 13, 3075-3078.
3) (a) Asymmetric Catalysis in Organic Synthesis; Noyori, R., Ed.; Wiley-
Interscience: New York, 1994. (b) ComprehensiVe Asymmetric Catalysis;
Jacobsen, E. N., Pfaltz, A., Yamamoto, H., Eds.; Springer: Berlin, 1999;
Vol. 1. (c) Catalytic Asymmetric Synthesis, 2nd ed.; Ojima, I., Ed.; Wiley-
VCH: New York, 2000.
(
(6) 5-Fc ) 1, 1′-bis(2,5-dialkylphospholano)ferrocene
(7) COD ) 1,5-cyclooctadiene
(
(8) (a) Burk, M. J.; Gross, M. F. Tetrahedron Lett. 1994, 35, 9363-9666. (b)
Berens, U.; Burk, M. J.; Gerlach, A.; Hems, W. Angew. Chem., Int. Ed.
2000, 39, 1981. (c) Pye, P. J.; Rossen, K.; Reamer, R. A.; Tsou, N. N.;
Volante, R. P.; Reider, P. J. J. Am. Chem. Soc. 1997, 119, 6207-6208. (d)
Burk, M. J. Acc. Chem. Res. 2000, 33, 363-372 and references therein; (e)
Henschke, J. P.; Burk, M. J.; Malan, C. J.; Herzberg, D.; Peterson, J. A.;
Wildsmith, A. J.; Cobley, C. J.; Casy, G. AdV. Synth. Catal. 2003, 345,
300-307.
(
4) For industrial examples of asymmetric hydrogenation, see: Blaser, H. U.;
Spindler, F.; Studer, M. Appl. Catal. A: Gen. 2001, 221, 119-143.
5) Takeda, H.; Tachinami, T.; Hosokawa, S.; Aburatani, M.; Inoguchi, K.;
Achiwa, K. Chem. Pharm. Bull. 1991, 39, 2706-2708.
(
1
0.1021/op0256183 CCC: $25.00 © 2003 American Chemical Society
Vol. 7, No. 3, 2003 / Organic Process Research & Development
•
407
Published on Web 04/11/2003